Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 691751 in Healthy Asian Males
NCT02057835Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BI 691751 in atherosclerosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Participants With Drug Related Adverse Events at 31 days. Started Mar 2014; status: completed.
02
Drugs
BI 691751
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02057835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057835.